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Effects of new analogues of vitamin D on bone cells: Implica- ized by being capable of contributing to a state of para-
tions for treatment of uremic bone disease. thyroid hormone (PTH) suppression and reduction of
Background. The use of calcitriol in the treatment of uremic PTH-driven low bone turnover, have been implicatedhyperparathyroidism and renal osteodystrophy is limited in
[4–6]. These include intensive use of vitamin D and othermany patients by hypercalcemic side-effects. New less calcemic
calcemic therapies, such as oral calcium salts and rela-analogues of calcitriol are being developed, and some are under
clinical evaluation. To investigate whether these compounds tively high dialysate calcium concentrations in the treat-
possess important differences in their action on bone cells, ment of uremic hyperparathyroidism and renal osteodys-
we have studied their effects [with and without parathyroid trophy (ROD) [7].
hormone (PTH)] on the release and synthesis of the resorptive
Several new calcitriol analogues are becoming avail-osteotropic cytokine, interleukin-6 (IL-6).
able as alternative agents. Most of these share a reducedMethods. MG 63 and SaOS-2 human osteoblastic cell lines
were cultured for 6 or 24 hours in media containing calcitriol, tendency (compared with calcitriol) to raise extracellular
the sterols of interest, or 1–34 synthetic PTH. IL-6 release was fluid calcium, which is a useful property when used to treat
assayed by commercially available enzyme-linked immunosor- severe cases of hyperparathyroidism, but one that might
bent assay. IL-6 mRNA levels were assessed by reverse tran-
allow profound PTH suppression in large numbers of pa-scriptase-polymerase chain reaction.
tients, with a concomitantly increased risk of developingResults. We found that calcitriol and paricalcitol behaved
in a similar fashion, resulting in increased IL-6 release only at ABD. Whether these analogues possess clear-cut quali-
higher concentrations (1027 to 1029 m). In contrast, 22-oxacalci- tative differences in their effects on the different target
triol and 1,25-dihydroxydihydrotachysterol2 stimulated release tissues or whether the reported differences may merely be
to a similar extent but at concentrations three to four orders a function of their differing potencies remains contentious.of magnitude lower (10211 to 10213 m), despite being less potent
The ability of a calcitriol analogue, at concentrationsas suppressers of parathyroid function than calcitriol. Studies
compatible with those achieved during the treatment ofof IL-6 mRNA showed a similar pattern of concentration and
cell line-dependent transcription. uremic hyperparathyroidism, to stimulate the release of
Conclusions. Compounds stimulating IL-6 release at con- interleukin (IL)-6 from the osteoblast might be thera-
centrations achievable during the treatment of uremic hyper- peutically exploitable by helping to maintain an appro-parathyroidism might favor continuing linked bone formation
priate balance between the activators and suppressersand resorption and thereby avoid adynamic bone disease while
of bone cell activity. Such an agent might achieve thestill allowing profound suppression of PTH.
twin objectives of profound parathyroid cell suppression
with maintenance of normal bone turnover.
To address these issues, we have used two culturedThere has been an increase in the reported incidence
human osteoblastic-like cell lines to examine the in vitroof nonaluminum-related adynamic bone disease (ABD)
effects of calcitriol and three of these new analogues,since it was first described [1], with up to 49% of hemodi-
paricalcitol, 22-oxacalcitriol (OCT), and 1,25-dihydroxy-alysis patients [2, 3] affected. Various factors, character-
dihydrotachysterol2 [1,25(OH)2DHT2] (molecular struc-
tures shown in Fig. 1), on the release of the osteotropicKey words: renal osteodystrophy, calcitriol, parathyroid hormone,
SaOS-2 cells, adynamic bone disease, interleukin-6, MG 63 cells, uremic and predominantly resorptive cytokine, IL-6 [8–11]. IL-6
bone disease. is synthesized and released from osteoblasts in response
to resorptive influences [12] and increases recruitmentReceived for publication December 23, 1997
of immature hemopoietic precursors to the mature func-and in revised form September 2, 1998
Accepted for publication September 2, 1998 tioning osteoclastic pool [13, 14]. IL-6 has been reported
to play a role in the pathogenesis of a wide variety of 1999 by the International Society of Nephrology
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Fig. 1. Molecular structures of calcitriol, par-
icalcitol, 22-oxacalcitriol (OCT), and 1,25
(OH)2DHT2.
conditions characterized by increased bone resorption mal essential media (a-MEM), 10% fetal calf serum
(FCS; GIBCO BRL Life Technologies, Grand Island,[15–22], including ROD [23].
NY, USA), and antibiotics (benzylpenicillin 100 units/The calcitriol analogues chosen (paricalcitol, OCT,
ml, streptomycin 10 mg/ml, amphotericin 2.5 mg/ml),and 1,25(OH)2DHT2) are less calcemic than calcitriol
hereafter called medium. Cells were then plated out into[24–26], and in addition, paricalcitol may be less phos-
24-well plates at a density of 200,000 cells/well. Cellsphatemic. Both OCT and paricalcitol are undergoing (or,
were allowed to adhere for 24 hours before media werein paricalcitol’s case, have completed) phase III clinical
aspirated. Cells were washed and then further incubatedtrials [27, 28]. Dihydrotachysterol2 is an effective therapy
in a-MEM, antibiotics, and 10% charcoal-stripped fetalfor ROD [29, 30], and we have already identified
calf serum (CS-FCS; hereafter referred to as CS-1,25(OH)2DHT2 as its most potent metabolite in terms
medium), providing a nonstimulating growth-arrestedof PTH suppression both in vitro and in vivo and also
environment for a further 24 hours.as a stimulator of calcitriol-responsive genes in other
Cells were then incubated for either 6 or 24 hoursintact cell systems [31]. The contention that there may
with the sterols of interest in CS-medium at a range ofbe therapeutically exploitable differences between these
concentrations from 1027 to 10213 m. Negative controlsanalogues is consistent with preliminary reports (in a
were provided by incubation with CS-medium withouturemic canine model) of a reduction in ABD when using
sterol, and further wells were incubated with interleukin-OCT to control secondary hyperparathyroidism [32].
1b (IL-1b) at 100 activity units/ml as a positive control
for the release of a wide spectrum of cytokines from
METHODS osteoblastic-like cells [15]. In addition, a dose-response
MG 63 and SaOS-2 cells were cultured (in a 95% curve was constructed for the release of IL-6 from MG
63 cells after a 24-hour incubation with human recombi-humidified atmosphere with 5% CO2 at 378C) in a-mini-
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Fig. 2. Release of interleukin (IL)-6 from
MG 63 cells after incubation with the sterols
for six hours. *P , 0.05 significance compared
with CS-medium control values. N 5 36 for
each sterol.
nant IL-1b at a concentration range of 0 to 50 ng/ml nant human IL-6, itself calibrated against the World
Health Organization First International Standard (IL-6(R&D Systems, Abingdon, Oxon, UK). At the end of
the allotted incubation periods, media were removed 89/548; National Institute for Biological Standards and
Control, Potters Bar, Hertfordshire, UK). This assay hasand stored at 2208C for no longer than one month. Cells
were washed with phosphate-buffered saline (PBS) and minimum detection limits of less than 1 pg/ml, an intra-
assay variation of less than 6% and interassay variationwere subjected to three freeze/thaw cycles between
2708C and room temperature to allow cell lysis and of less than 14% and has been shown to be specific for
IL-6 [33]. In selected samples, IL-1b was also assayedestimation of total cellular protein. All experiments were
performed in at least quadruplicate and were repeated by a similar technique (R&D Systems, Abingdon, UK).
This assay also possesses detection limits of less than 1three times.
Additional experiments were set up following an iden- pg/ml.
tical protocol, and the cells were incubated with 1–34
Assessment of mRNA levelsfragment synthetic PTH (Sigma-Aldrich Ltd., Mulan,
MG 63 and SaOS-2 cells were cultured in a similarItaly) at 10210 m and 10211 m (a range of concentrations
fashion to the previous set of experiments to study thesimulating moderate to severe hyperparathyroidism),
release of cytokines from these cell lines, except that theboth alone and in combination with the sterols of in-
cells were plated out into 6-well plates at a density ofterest.
800,000 cells/well and were allowed to adhere for 24
Cytokine assay hours before media were aspirated. The cells were
washed with cold PBS and were then further incubatedInterleukin-6 was measured in all media by a quantita-
tive sandwich enzyme-linked immunosorbent assay tech- in a-MEM, antibiotics, and 10% CS-FCS, providing a
nonstimulating growth-arrested environment, for a fur-nique (Eurogenetics, Teddington, Middlesex, UK). The
optical density of the final chromogen was assessed (at ther 24 hours.
Cells were then incubated for either 3, 6, or 24 hours450 nm) and compared with a standard curve of recombi-
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Fig. 3. Release of IL-6 from MG 63 cells after
incubation with the sterols for 24 hours. *P ,
0.05 significance compared with CS-medium
control values. N 5 64 for each sterol.
with the sterols of interest in CS-medium at a range of nents and inactivation of endogenous RNAses. Poly(A)
tracts on the mRNA molecules efficiently bind to oli-concentrations from 1027 to 10213 m. Negative controls
were provided by incubation with CS-medium without go(dt) attached to a cellulose resin. The mRNA was
finally eluted and quantitated by spectrophotometry.sterol, and further wells were incubated with IL-1b at
100 activity units/ml as a positive control for the tran- Typically, 1 to 2 mg of RNA were recovered after each
purification. Samples were then concentrated by precipi-scriptional stimulation of a wide spectrum of cytokines
in osteoblastic-like cells. All experiments were per- tation.
formed at least three times. Media were aspirated, and
Reverse transcriptase-polymeraseadherent cells were washed three times with PBS before
chain reaction (RT-PCR)being trypsinized (0.05%) off and pelleted by centrifuga-
RNA was used as a template for first strand cDNAtion prior to mRNA extraction.
synthesis using commercially available Bulk First Strand
Extraction of mRNA Reaction Mix, which contained Moloney Murine Leuke-
mia Virus reverse transcriptase (supplied in the FirstmRNA was isolated directly from cultured cells with-
out prior purification of total RNA, using the commer- Strand cDNA Synthesiz Kit; Pharmacia Biotech). This
reaction was primed with the supplied Not-I-d(T)18 Bi-cially available QuickPrept Micro mRNA Purification
Kit (Pharmacia Biotech, Quebec, Canada). This kit functional Primer.
cDNA made from approximately 200 ng of mRNAyields a preparation of RNA that consists of 95%
mRNA. The process involves extraction of RNA from was found to be the optimum load for the PCR reaction
conditions used, preventing plateauing of the final signalpelleted cells with a buffered solution containing a high
concentration of guanidinium thiocyanate, a chaotropic and precluding differentiation of the amount of tran-
scription. Relative RT-PCR was performed using IL-6salt ensuring the rapid solubilization of cellular compo-
McIntyre et al: Noncalcemic analogues of vitamin D504
Fig. 4. Release of IL-6 from SaOS-2 cells
after incubation with the sterols for 24 hours.
P , 0.05 significance compared with CS-
medium control values. N 5 32 for each sterol.
oligonucleotide primers, specifically designed using the which was then subjected to 35 cycles of 938C-60 seconds,
608C-60 seconds, and 728C-45 seconds, followed by ahuman genome mapping program to span introns. The
forward primer sequence was 59-CTGCTCCTGGTGT further 10 minutes at 728C for final primer extension, as
summarized in Figure 3.TGCCT-39, and the reverse sequence was 59-CCTGCA
GCCACTGGTTCT-39. This resulted in a 511 bp DNA Fragment detection was achieved after separation by
electrophoresis in a Tris-borate ethylenediaminetetra-fragment. Oligonucletide primers for glycerolaldehyde
3-phosphate dehyrogenase (GAPDH) were used as the acetic acid buffer. A Hinc II digest DNA fragment ladder
internal “invariant” standard (Clontech Laboratories Inc., (Pharmacia Biotech) was run parallel with the PCR prod-
Palo Alto, CA, USA). The upstream sequence 59 to 39 ucts. Homology of the 511 base pair PCR product with
was TGAAGGTCGGAGTCAACGGATTTGGT, and the IL-6 sequence was confirmed by sequencing using
the downstream sequence 39 to 59 was CATGTGGGCC Taq cycling with fluorescently labeled dye terminators.
ATGAGGTCCACCAC. These primers resulted in a Visualization was by ethidium bromide staining, followed
single PCR product of 983 base pairs. PCR reactions con- by gel photography on a ultraviolet light box with Polaroid
tained 13 ml of first strand cDNA template, 10 ml 10 3 type 665 film to yield a negative, prior to quantitation of
PCR buffer (500 mm KCl, 100 mm Tris, 15 mm MgCl2, the visible bands on the photograph by scanning densitom-
0.01% gelatin), 0.5 ml dNTP mix (Pharmacia), 1 ml of etry (Biorad GS-670 Imaging Densitometer; Bio-Rad,
upstream/downstream IL-6 primers, and 0.5 ml of up- Hemel Hempstead, Hertfordshire, UK). Density of the
stream/downstream GAPDH primers made up to 75 ml IL-6 band is expressed in the results as the ratio of the
with sterile water. Negative controls did not contain any optical density of IL-6 band/GAPDH band.
DNA template. PCR was performed in a Perkin Elmer
Total protein assayThermal cycler. After one minute at 948C, 2.5 units of
Taq DNA polymerase (Boehringer Mannheim, Mann- Cellular protein was assayed using the Bradford dye-
binding protein assay (Bio-Rad) in a spectrophotometricheim, Germany) were added to each PCR reaction,
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Fig. 5. Dose response curve for IL-6 release from MG 63 cells in
response to 24-hour incubation with exogenous IL-1b. Fig. 6. Effect of the amount of cDNA used per PCR reaction on the
optical density of the final product.
microtiter-based format. Absorbance was measured at centrations of 1029 m and higher (P 5 0.004 for calcitriol
595 nm and compared with a standard curve prepared and paricalcitol at 1027 m and P 5 0.01 for both at a
using known concentrations of protein. concentration of 1029 m). After 24 hours (Fig. 3) of incu-
bation, the pattern of release was similar; paricalcitol
Alkaline phosphatase detection and calcitriol achieved a twofold to fourfold increase
(peak level 348 pg/ml 6 56 over and 808 pg/ml 6 62Alkaline phosphatase (ALP) activity of the cultured
cells was confirmed by staining confluent flasks with 5- for calcitriol and paricalcitol, respectively) over controls
(163 pg/ml 6 25.6) at similar high concentrations (P ,bromo-4-chloro-3-indoyl phosphate. Positive blue stain-
ing was achieved in the presence of ALP with the color 0.0001 at 1027 m and P 5 0.02 at 1029 m).
The results of IL-6 release from SaOS-2 cells werebeing intensified by oxidation with nitro blue tetrazolium
chloride, both from Boehringer Mannheim. markedly different (Fig. 4). At six hours, there were no
detectable differences in the IL-6 levels in the media
Statistical analysis from cells treated with sterols over control media. IL-6
levels were extremely low, with all levels less than 7Results were analyzed by analysis of variance and were
pg/ml. After 24 hours of incubation, IL-6 levels wereand paired Student’s t-tests. A P of less than 0.05 was
increased by a factor of twofold to sixfold (peak levelsconsidered significant. Results are expressed as mean 6
32 pg/ml 6 7.5 and 11.7 pg/ml 6 3.1 for paricalcitol andstandard error of the mean, unless otherwise stated.
calcitriol, respectively, CS media 5.1 pg/ml). Again, this
increase was only seen at concentrations greater than
RESULTS 1029 m (P 5 0.0002). The concentration of IL-6 seen in
Calcitriol and paricalcitol the SaOS-2 experiments was approximately 10% of those
seen in the MG 63 experiments.Interleukin-6 was released from the cells into the me-
dia in a sterol concentration-dependent manner (Fig.
OCT and 1,25(OH)2DHT22). At six hours of incubation with the MG 63 cells,
paricalcitol and calcitriol both resulted in a twofold to In contrast, incubation of the MG 63 cells with OCT
and 1,25(OH)2DHT2 for six hours also resulted in a two-fourfold increase in IL-6 release (peak 338 pg/ml 6
74,568 mg/ml 6 107 for calcitriol and paricalcitol, respec- fold to threefold increase in IL-6 release [peak 325 pg/ml 6
82 and 498 pg/ml 6 18 for OCT and 1,25(OH)2DHT2,tively) over the control media (cells incubated in CS-
medium) and achieved statistical significance only at con- respectively] over baseline controls (135 pg/ml 6 14.5).
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Fig. 7. Effect of the vitamin D sterols on IL-6
mRNA levels in MG 63 cells after six hours.
*Indicates statistically significant difference
between sterol-treated mRNA level and con-
trol mRNA level (P , 0.05, N 5 3).
This was seen only at below 1029 m (P 5 0.02 at both 24 hours, respectively, as compared with unstimulated
baseline levels (123 pg/ml 6 8 and 171 pg/ml 6 23.6,10211 m and 10213 m, for both sterols; Fig. 2). The same
pattern of release was seen after 24 hours of incubation, respectively). Peak IL-6 levels in media from SaOS-2
cells were 1.9 pg/ml 6 0.5 and 6.9 pg/ml 6 1.1 at 6 andagain with only the lower concentrations resulting in an
increase in the IL-6 level [peak 503 pg/ml 6 89 and 323 24 hours, respectively, as compared with unstimulated
baseline levels (2.2 pg/ml 6 0.6 and 7.2 pg/ml 6 1.4,pg/ml 6 25 for OCT and 1,25(OH)2DHT2, respectively;
P 5 0.025 at 10211 m for OCT; and P 5 0.008 for respectively). This lack of effect was seen both in IL-6
release after incubation with either concentration of1,25(OH)2DHT2 at 10213 m; Fig. 3].
The results of IL-6 release from the SaOS-2 cells lines PTH alone and in a lack of modulation of the release
of IL-6 by the vitamin D sterols, again at either of thewere similar to those seen with calcitriol and paricalcitol.
There was again no detectable difference in IL-6 levels two concentrations.
in the media from treated cells over control media after
IL-1b stimulation and releasesix hours of incubation. IL-6 levels were extremely low,
with all levels less than 3 pg/ml. After 24 hours of incuba- Incubation with IL-1b resulted in a 10- to 15-fold in-
crease over control levels of IL-6 in both cell lines andtion at concentrations of 1027 m, IL-6 levels were in-
creased by about twofold [peak levels 11.8 pg/ml 6 3 at both time points (MG 63 cells were 16,520 pg/ml 6
2850 and 62,000 pg/ml 6 8300 at 6 and 24 hours, respec-and 13.3 pg/ml 6 2.7 for OCT and 1,25(OH)2DHT2,
respectively; Fig. 4]. tively; SaOS-2 cells were 1420 pg/ml 6 1342 and 7180
pg/ml 6 1980 at 6 and 24 hours, respectively). IL-1b levels
Effect of PTH were not significantly increased in the media harvested
from either of the cell lines after incubation with PTHParathyroid hormone did not have any effect on cyto-
kine release by either cell line after 6 or 24 hours of or calcitriol/analogues (6 pg/ml 6 0.8 as compared with
5.2 pg/ml 6 1.5 baseline control values in CS-medium).incubation. Peak IL-6 levels in media from MG 63 cells
were 113 pg/ml 6 12 and 193 pg/ml 6 14.3 at 6 and Further experiments incubating the cells with media con-
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Fig. 8. Effect of the vitamin D sterols on IL-6
mRNA levels in MG 63 cells after 24 hours.
*Indicates statistically significant difference
between sterol-treated mRNA level and con-
trol mRNA level (P , 0.05, N 5 3).
taining IL-1b for 24 hours revealed a proportional IL-6 paricalcitol 0.64 6 0.07, P 5 0.02; control 0.35 6 0.037)
in IL-6 mRNA at the highest concentration of 1027 m.response to an increasing concentration of IL-1b (Fig.
5). The observed levels of IL-1b released from the cells At this concentration, 1,25(OH)2DHT2 and OCT were
not associated with an increase (0.42 6 0.1 and 0.31 6themselves being below the minimal concentration re-
quired to elicit an IL-6 response in this cell system. 0.089, respectively). At the lowest concentration of
10211 m, calcitriol and paricalcitol did not result in an
mRNA levels increase in IL-6 mRNA compared with control values
(0.3 6 0.06 and 0.3 6 0.09, respectively). In contrast,Initial assessment of the density of the PCR product
1,25(OH)2 DHT2 and OCT at this concentration led toband as a function of the amount of mRNA that was
significantly higher levels of IL-6 mRNA (0.78 6 0.2,used in the first strand reaction (Fig. 6) revealed the
P 5 0.03, and 0.64 6 0.1, P 5 0.03). Cells incubated withexpected S-shaped curve. Using 200 ng of mRNA al-
IL-1b as a positive control for cytokine transcriptionlowed twofold to threefold differences in mRNA to be
exhibited a threefold increase in mRNA (1.22 6 0.2).detected and differentiated after the RT-PCR process.
The pattern of IL-6 transcription demonstrated at sixThe use of more than 500 ng cDNA resulted in a plateau-
hours was similar to that seen at 24 hours (Fig. 8).ing of the optical density and loss of sensitivity in the
Calcitriol and paricalcitol increased levels significantlydifferentiation of different amounts of the original RNA.
over negative control at the highest concentration of
MG 63 cells 1027 m only (1.5 6 0.3, P 5 0.03, 1.49 6 0.35, P 5 0.03,
and 0.56 6 0.07, respectively).There was no detectable IL-6 mRNA from the cells
harvested after three hours of incubation with the vita- There were no effects of 1,25(OH)2DHT2 or OCT at
this concentration (0.365 6 0.015, 0.75 6 0.16, respec-min D analogues. At six hours (Fig. 7), calcitriol and
paricalcitol resulted in a 50% to 70% increase over CS- tively). At 10211 m, calcitriol and paricalcitol resulted
in no increase (0.62 6 0.07, 0.81 6 0.14, respectively),FCS negative control values (calcitriol 0.52 6 0.11, NS;
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Fig. 9. Effect of the vitamin D sterols on IL-6
mRNA levels in SaOS-2 cells after 24 hours.
*Indicates statistically significant difference
between sterol-treated mRNA level and con-
trol mRNA level (P , 0.05, N 5 3).
whereas both 1,25(OH)2DHT2 and OCT were associated nitro blue tetrazolium chloride and 5-bromo-4-chloro-
with twofold to threefold increases (0.92 6 0.2, NS, 3-indoyl phosphate in keeping with their osteoblastic
1.34 6 0.05, P 5 0.001, respectively). IL-1b increased lineage.
IL-6 mRNA levels to 1.34 6 0.19, compared with the
Total cellular proteinnegative control.
There was no increase in total extracted cellular pro-
SaOS-2 cells tein over growth-arrested control cells as a result of incu-
There was no IL-6 mRNA detectable by RT-PCR bation with calcitriol, noncalcemic calcitriol analogues
after either three or six hours of incubation with calcitriol with or without PTH, or incubation with PTH alone.
or the other analogues under investigation. At the 24-
hour time point, all of the sterols were associated with
DISCUSSIONsignificant increases in IL-6 mRNA levels only at the
We have demonstrated that calcitriol, paricalcitol,higher concentration of 1027 m—calcitriol 0.83 6 0.052,
OCT, and 1,25(OH)2DHT2 are capable of stimulating theP 5 0.003; paricalcitol 1.1 6 0.2, P 5 0.02; 1,25
release of IL-6 from osteoblastic-like cells. Furthermore,(OH)2DHT2 1.3 6 0.23, P 5 0.017; OCT 0.83 6 0.08,
this release varies in a concentration-dependent manner.P 5 0.008; and CS-FCS control 0.37 6 0.05. At 10211 m,
Calcitriol and paricalcitol increase IL-6 release only atcalcitriol was 0.75 6 0.03; paricalcitol, 0.71 6 0.1;
concentrations above 1029 m (in MG 63 cells), whereas1,25(OH)2DHT2, 0.63 6 0.06; and OCT, 0.31 6 0.08.
OCT and 1,25(OH)2DHT2 provoked a similar increase,IL-1b caused an increase to a IL-6/GAPDH ratio of
but only at concentrations far lower than 1029 m. Thus,1.38 6 0.4 (Fig. 9).
OCT and 1,25(OH)2DHT2 are more potent than calcitriol
ALP activity in the stimulation of IL-6 release from osteoblastic cells,
but less so when used to suppress PTH secretion or toBoth of the cells lines demonstrated that they retained
ALP activity with positive staining after exposure to stimulate other vitamin D–responsive genes [29]. In the
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case of paricalcitol, the potency on bone cells is similar cells do not manifest an IL-6 response to PTH is consis-
to that of calcitriol, whereas as a suppresser of the para- tent with that of Littlewood et al, who failed to demon-
thyroids it is less potent than calcitriol [26]. Furthermore, strate IL-6 release from primary cultures in response to
these concentration- and sterol-dependent differences in PTH (predominantly phenotypically mature cells) [37].
the release of IL-6 were also reflected in the levels of Oniya et al have recently described an increase in IL-6
IL-6 mRNA in both MG 63 and SaOS-2 cells. gene expression in SaOS-2 cells in response to PTH (as
With the SaOS-2 cell line, the effect on IL-6 release evidenced by promoter region studies), but do not report
was far smaller, with all of the sterols causing release only an increase in cytokine release itself [47].
at the higher concentrations. This cell line represents a We found no evidence of IL-1b release from either
more mature and terminally differentiated osteoblastic cell line as a result of stimulation by calcitriol or other
phenotype than the MG 63 line [34] and is known to compounds under study. In contrast, Lacey et al have
have a much lower constitutive release of the osteotropic reported calcitriol-induced up-regulation of the IL-1b
cytokines [15]. The relative unresponsiveness of the receptor and have postulated an autocrine action of IL-
SaOS-2 cells has also been reported in relation to T3 1b as the mechanism for increased IL-6 production in a
[35]. Bone is not a homogenous target tissue, and even murine osteoblastic cell line [48]. These divergent results
within one cell type, not all of the population respond may be explained by differences in the production and
in same way, or at all, to a stimulus. Osteoblastic maturity release of bone cytokines in murine (modeling) and hu-
is known to influence cellular responsiveness to PTH man (remodeling) skeletons. Our results do not support
[36] and T3 [35]. Littlewood et al found no IL-6 response the contention that IL-1b is implicated in the release of
to calcitriol (or PTH) from primary human osteoblast IL-6, at least in the human cell.
culture derived from surgical explants [37]. Such cultures
In conclusion, our findings show that in the osteoblast-have a homogeneous and predominantly terminally dif-
like cells we have studied, 1,25(OH)2DHT2 and OCTferentiated phenotype [38] and may be unrepresentative
increase IL-6 release, and probably synthesis, at clinicallyof those cells that are responsible for paracrine commu-
relevant concentrations. In contrast, calcitriol and pari-nication of that stimulus to the osteoclasts.
calcitol do not have these effects on either IL-6 releaseThese experiments were not designed to probe the
or transcription except at concentrations far higher thanmechanisms behind these observed differences. How-
achievable during therapy. This raises the possibility thatever, possible mechanisms are several and include differ-
1,25(OH)2DHT2 and OCT may allow coupled osteoclas-ences between the sterols in terms of vitamin D receptor
tic bone resorption while, at the same time, providing(VDR) and retinoic acid receptor interactions, or stabili-
profound PTH suppression. The studies of Geng et alzation of IL-6 transcripts. The tissue responsiveness to
in uremic dogs [32] provide some support for this view,calcitriol is known to depend, in part, on the degree
and if confirmed by further in vivo studies, there mayof VDR expression [39]; calcitriol up-regulates its own
be important implications for the prevention of ABDreceptor in a variety of tissues [40] and is capable of
while still avoiding the development of parathyroid nod-increasing the half-life of the VDR [41]. The effects of
ular hyperplasia and its consequences of eventual vita-OCT, 1,25(OH)2DHT2, and paricalcitol on the VDR are
min D treatment failure.largely unknown. Paricalcitol has recently been demon-
strated to have little effect on rat intestinal VDR numbers
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Parathyroid hormone had no effect on IL-6 release
Abbreviations used in this article are: ABD, adynamic bone disease;
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